GlassScriptPhysician profile
Sara I Ali
NPI 1467628255
$3,187.55
in general payments reported to CMS, 2019-2025
33 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.98 · 2020: $213 · 2021: $240 · 2022: $351 · 2023: $101 · 2024: $1,195 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $387.85 | 2020-2025 | Kisunla, Zepbound, Mounjaro |
| Novo Nordisk INC | $318.28 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $303.90 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $298.00 | 2022-2025 | Octrode, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $288.13 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.80 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $178.48 | 2020-2025 | |
| Alkermes, INC. | $177.81 | 2021 | |
| Amgen INC. | $109.67 | 2022-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $108.49 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $94.85 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $74.15 | 2020-2022 | |
| Dexcom, INC. | $72.92 | 2024-2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $64.38 | 2019-2025 | Tecentriq |
| Medtronic, INC. | $59.04 | 2024 | Intellis Adaptivestim |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.92 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $32.33 | 2025 | Rexulti |
| Eisai INC. | $30.69 | 2025 | |
| Sumitomo Pharma America, INC. | $30.02 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $23.91 | 2025 | Voquezna |
| Stryker Corporation | $23.10 | 2025 | Blueprint Patient Specific Instrumentation |
| Astellas Pharma US INC | $22.91 | 2024 | Veozah |
| Hologic Sales and Service, LLC | $20.93 | 2025 | Thinprep 2000 Processor, Aptima |
| Biocomposites INC | $20.25 | 2024 | |
| Phadia US INC. | $19.24 | 2025 | Immunocap |
| Lundbeck LLC | $17.64 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $16.58 | 2025 | Opsynvi, Uptravi |
| Amarin Pharma, INC. | $14.37 | 2020 | |
| Sanofi Pasteur INC. | $14.18 | 2020 | |
| Bausch Health US, LLC | $13.44 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.50 | 2020 | |
| Merck Sharp & Dohme LLC | $11.01 | 2020 | |
| Impulse Dynamics (USA) INC. | $10.78 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.